Wednesday, 18 Jul 2018

RA/Inflammatory arthritis

Datesort ascending Type Title Save
23 Apr 2018 Social FDA Arthritis panel on Baricitinib approval in RA votes 10-5 in favor of 2 mg dose but voted 10-5 Against baricitinib 4 mg dose. Concerns about safety of 4 mg dose, esp VTE, thrombophilia
23 Apr 2018 Social FDA Arthritis advisory panel voting in progress. Early votes unanimously in favor of baricitinib efficacy at 4 mg (15-0) or 2mg(14-1 unfavorably)
22 Apr 2018 Social RT @NatRevRheumatol: #TrendingNow Chester Oddis & Rohit Aggarwal discuss the treatment of myositis https://t.co/dcPx9bY1DX #myositis #treat…
20 Apr 2018 Social RT @RheumNow: RHEUMATOLOGIST VOTE: Active RA, SJC=5, fails 1st TNF inhibitor, which is your next choice:
20 Apr 2018 Social Fostamatinib, a spleen tyrosine kinase (Syk)inhibitor, that failed in #RA, has been FDA approved for use in adult with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The drug will be called Tavalisse. https://t.co/uQVpV6NioD
19 Apr 2018 Social Study of 1181 Systemic Sclerosis pts finds 3.4% w/ hx of VTE events= VTE incidence of 2.7 per 1000 pt-yrs (equal to general population). Risk factors for VTE were PAH, peripheral arterial disease, Scl-70+, anticardiolipin Abs (OR 2.45-5.7) https://t.co/AgBb7tGvGh
19 Apr 2018 Social RHEUMATOLOGIST VOTE: Active RA, SJC=5, fails 1st TNF inhibitor, which is your next choice:
19 Apr 2018 News Shared Epitope - Smoking Pathogenic Link Clarified
17 Apr 2018 News Kineret Approved for Still's Disease in EU
16 Apr 2018 Social 2996 HIV+ patients on HRT finds 113 w/ Rheumatic disease, lead by AVN 39 (1.3%), psoriasis 28 (1%), RA 7, PsA 6, & SLE 6pts. HIV Males 1.7 times more likely to have a rheum Dz. Hep C incr the risk of RD. RD Risk in HIV+ appears same as gen population. https://t.co/32PiLEeKgI
13 Apr 2018 News Mayo and UAB Awarded $1 million Grant for Patient Research
12 Apr 2018 Social In a historical prospective cohort study, PPI use in RA (1:4) was associated with a doubling of risk for acute kidney injury (HZ 2.30: 1.26-4.20) but was only 2.2 AKI per 1000PY in RA/PPI+ vs 0.9/1000PY in RA without PPI. Thus depends on need for PPI https://t.co/TxqjAR7Y5Y
09 Apr 2018 News Defining Refractory Rheumatoid Arthritis
09 Apr 2018 Social New RheumNow Survey on the risk of Venous-Thromboembolic Events in RA - Rheums vote here: (VTE is usually due to?) https://t.co/rmilEeZthL
09 Apr 2018 Social Abbvie announces results of its JAK inhibitor upadacitinib ouperforming adalimumab with ACR20 71%, ACR50 of 45%, 29 DAS remission, LDAS 45% at week 12 https://t.co/4bQ6FOkLhc
08 Apr 2018 Social 56 myositis patients with anti‐NXP‐2 autoantibodies (18 with and 38 without calcinosis) showed that NXP‐2 Ab levels correlate w/ disease activity, espcially in those without calcinosis; suggesting calcinosis defines 2 phenotypes. https://t.co/oxtpwUbtJv
06 Apr 2018 Social RheumNow Wk in Review is up! The Temporal Artery Biopsy Letdown! Listen https://t.co/HXSTSfAwlX or watch on the website https://t.co/WN6VYQwSQp
06 Apr 2018 News Uveitis in JIA: Screen All, Treat Early
05 Apr 2018 Social Swiss study of 244 pregnancies finds RA and axSpA have significantly higher risk of pregnancy complications (DM, preeclampsia, infection, small babies, preterm delivery). Active disease predicts preterm delivery in both RA (OR 3.9) & axSpA (OR 13.8) https://t.co/I02unIG499
05 Apr 2018 Social EMR study of 116 obese/overweight RA clinic pts shows that the 31% lost ≥5 kg during follow-up had 3 fold chance of disease activity improvement (CDA >5). https://t.co/JIanV3FuE8